Loading...
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.
Lillian, S De Bono, J Higano, C Shapiro, G Brugger, W Mitchell, P Colebrook, S Klinowska, T Barry, S Dean, Emma J
Lillian, S
De Bono, J
Higano, C
Shapiro, G
Brugger, W
Mitchell, P
Colebrook, S
Klinowska, T
Barry, S
Dean, Emma J
Citations
Altmetric:
Abstract
Description
Date
2016-12
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate. 2016, 69 (Suppl 1):S19 European Journal of Cancer